Genetic testing could streamline heart therapy:
This article was originally published in Clinica
A genetic test for the ACE (angiotensin converting enzyme) gene could predict which patients are likely to benefit from beta blockers in the treatment of congestive heart failure, according to a US study. Researchers from the University of Pittsburgh in Pennsylvania evaluated 328 patients with heart failure who were being treated with either ACE inhibitors, angiotensin receptor blockers or beta blockers. They found that patients with two deletion (D) alleles, known as ACE DD, had "dramatic benefits" when using beta blockers compared with the other medication. The study appeared in Circulation (March 27).